Detail
CJC-1295 Overview
Growth hormone releasing hormone (GHRH) has been modified a number of times to produce analogues that preserve some of the hormone’s effects while eliminating others. One of those modifications, CJC-1295, consists of just the first 29 amino acids of GHRH. This analogue of GHRH, which is technically a maleimido derivative of hGRF(1-29), was created in an effort to produce a more soluble GH secretagogue that is easier to produce in large quantities but still preserves the physiologic actions of GHRH.
CJC-1295 Versus CJC-1295 DAC
CJC-1295 is a modified version of the first 29 amino acids of GHRH, which means it is chemically similar to other GHRH analogues, like Sermorelin. It is most similar to modified GRF (1-29), but the two peptides are not identical. A great deal of confusion arises because of the similarities between these peptides and because CJC-1295 was originally created with an added chemical compound called the drug affinity complex (DAC).
DAC is added to the molecule, with the help of a lysine linker, to protect the peptide while it circulates in the blood stream. By allowing peptides to bind to the common blood protein albumin, DAC helps to ensure that the half-life of CJC-1295 is much longer than similar molecules like GRF (1-29).
CJC 1295 with DAC 5mg
Important Notices:
You Must be a researcher and over 18 years old to purchase.
· This product is sold for scientific research purposes only.
· Product is provided as a lyophilized (freeze-dried) powder in a sealed, sterile vial.
· The quantity on the label refers to the total amount of product inside each vial.
· Additional lab supplies are required for conducting research such as bacteriostatic water for reconstitution, syringes & needles to draw from the vials, and alcohol prep pads for sanitizing vial stoppers prior to needle insertion.
· Vial appearance, label, seal and cap colors may vary from product photos.
